Dr. Byrd Updating the Trial Data on Ibrutinib for CLL (Chronic Lymphocytic Leukemia)

This week's new post on the CLL Society website http://cllsociety.org is an update of the data from trials with ibrutinib in treatment-naïve and relapsed patients presented by Dr. Byrd from an interview done at the CRC (CLL Research Consortium) meeting in San Diego in April 2015.
Dr. Byrd presents the long-term data from patients having received almost three years of treatment with ibrutinib for chronic lymphocytic leukemia. The data are increasingly positive, however there are still concerns with relapse, especially in those with genetic instability such as those with 17p deletion or a complex karyotype.
Still the news is good.
For my take away points, and Dr. Byrd's upbeat message from the short part 2 of our interview at the CRC meeting, please here.I am part of this cohort as I am now 40+ months on ibrutinib with both 17p deletion or a complex karyotype, so this data is something I watch closely.
Stay strong.
We are all this together
Brian Koffman
Volunteer Medical Director of the CLL Society
http://cllsociety.orghttp://bkoffman.blogspot.comIf you want a personal response, or just want to stay in touch, please email me at bkoffmanMD@gmail.com. I have no other way of contacting. Thanks. Stay strong. After all, we are all in this together. And please visit our website: http://cllsociety.org for the latest news and information.